

Antifungal resistance and stewardship: a knowledge, attitudes and practices survey among pharmacy students at the University of Zambia; findings and implications

Steward Mudenda ^{1,2*}, Scott Kaba Matafwali ³, Moses Mukosha¹, Victor Daka ⁴, Billy Chabalenge⁵, Joseph Chizimu², Kaunda Yamba², Webrod Mufwambi¹, Patrick Banda¹, Patience Chisha¹, Florence Mulenga⁶, McLawrence Phiri⁷, Ruth Lindizyani Mfunze³, Maisa Kasanga ⁸, Massimo Sartelli⁹, Zikria Saleem¹⁰ and Brian Godman^{11,12,13}

¹Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka PO Box 50110, Zambia; ²Antimicrobial Resistance Coordinating Committee, Zambia National Public Health Institute, Lusaka, Zambia; ³Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; ⁴Department of Public Health, Michael Chilufya Sata School of Medicine, Copperbelt University, Ndola PO Box 71191, Zambia; ⁵Department of Medicines Control, Zambia Medicines Regulatory Authority, Lusaka PO Box 31890, Zambia; ⁶Conservation Department, World Wide Fund For Nature (WWF Zambia Country Office), Lusaka PO Box 50551, Zambia; ⁷Department of Pharmacy, Maina Soko Medical Center, Woodlands, Lusaka PO Box 320091, Zambia; ⁸Department of Epidemiology and Biostatistics, Zhengzhou University, College of Public Health, 100 Kexue Avenue, Zhengzhou, Henan 450001, China; ⁹Department of Surgery, Macerata Hospital, Macerata, Italy; ¹⁰Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan; ¹¹School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria 0208, South Africa; ¹²Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow G4 0RE, UK; ¹³Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emirates

*Corresponding author. E-mail: steward.mudenda@unza.zm

Received 9 October 2023; accepted 5 December 2023

Introduction: Antifungal resistance (AFR) is a growing global public health concern. Little is currently known about knowledge, attitudes and practices regarding AFR and antifungal stewardship (AFS) in Zambia, and across the globe. To address this evidence gap, we conducted a study through a questionnaire design starting with pharmacy students as they include the next generation of healthcare professionals.

Methods: A cross-sectional study among 412 pharmacy students from June 2023 to July 2023 using a structured questionnaire. Multivariable analysis was used to determine key factors of influence.

Results: Of the 412 participants, 55.8% were female, with 81.6% aged between 18 and 25 years. Most students had good knowledge (85.9%) and positive attitudes (86.7%) but sub-optimal practices (65.8%) towards AFR and AFS. Overall, 30.2% of students accessed antifungals without a prescription. Male students were less likely to report a good knowledge of AFR (adjusted OR, AOR = 0.55, 95% CI: 0.31–0.98). Similarly, students residing in urban areas were less likely to report a positive attitude (AOR = 0.35, 95% CI: 0.13–0.91). Fourth-year students were also less likely to report good practices compared with second-year students (AOR = 0.48, 95% CI: 0.27–0.85).

Conclusions: Good knowledge and positive attitudes must translate into good practices toward AFR and AFS going forward. Consequently, there is a need to provide educational interventions where students have low scores regarding AFR and AFS. In addition, there is a need to implement strategies to reduce inappropriate dispensing of antifungals, especially without a prescription, to reduce AFR in Zambia.

Introduction

Antimicrobial resistance (AMR) is a term used to describe the ability of bacteria, fungi, parasites and viruses to overcome the lethal

effects of antimicrobial agents.^{1,2} AMR poses challenges in treating infections resulting in increased morbidity, mortality and costs, with AMR increasingly seen as the next pandemic unless addressed.^{3–7} Within AMR, antifungal resistance (AFR) is seen as an

increasing problem;^{8–12} however, the prevalence of AFR has been underestimated in the past.^{13,14} This misconception needs to be urgently addressed with a rise in fungal infections globally, particularly drug-resistant ones, further increasing morbidity and mortality rates from AMR.^{9,14–17} Currently, it is estimated that over 1.5 to 2 million people globally die each year from fungal infections, similar to the number of people dying each year from antibacterial resistance, with over a billion people currently affected by fungal diseases, which includes over 150 million people with severe fungal infections.^{10,11,18,19} The costs of treating patients with fungal diseases are also substantial, estimated at \$6.7 billion–\$7.2 billion annually in the USA alone in 2017 and 2018,^{6,20} with these costs expected to rise with increasing AFR.

Despite rising mortality and costs due to AFR, most emphasis, research and public health policies have primarily been focused on resistance to antibacterials and antivirals as opposed to antifungals.^{11,21} This skew has had unintended consequences of leaving AFR relatively neglected compared with antibiotic resistance (ABR), which is despite increasing concerns with AFR.^{9,13,22} This oversight has serious implications for the overall management of fungal infections, although this is starting to change with, for instance, the call for more research on AFR and the introduction of stewardship programmes to improve the utilization of antifungals.²³ For instance, in Zambia, Nowbuth *et al.*,²⁴ in their recent systematic review on published studies regarding the prevalence of AMR in Zambia, did not find any studies on AFR meeting their inclusion criteria. However, published studies exist on other resistant pathogens.²⁴

Some drivers of AMR include the inappropriate prescribing of antimicrobials including subtherapeutic dosing,^{8,13,25,26} exacerbated by the inappropriate dispensing of antimicrobials without prescriptions.^{27–29} Alongside this, low awareness, inadequate knowledge and poor attitudes and practices concerning the use of antimicrobials have further increased AMR as a result of their irrational use.^{29–32}

Antifungals are essential for effectively managing fungal infections.^{33–35} However, achieving their optimal use remains a challenge.³⁶ The use of antifungal medicines has increased in recent years due to the increased burden of fungal infections, especially among immunocompromised individuals.^{21,35,37} Some commonly used antifungals include fluconazole, amphotericin B, miconazole, itraconazole, voriconazole, ketoconazole, posaconazole, isavuconazole, caspofungin, anidulafungin and micafungin, which are used to treat fungal infections including candidiasis, meningitis, histoplasmosis and oral thrush.^{38–41} However, there are concerns with their overuse and misuse, exacerbated by the switching of some antifungals from prescription medicines to over-the-counter medicines, exacerbating AFR.^{38,42–44} Alongside this, an appreciable number of patients using antifungal treatments do so improperly, often failing to complete the full course, leading to AFR.^{45,46} Furthermore, AFR fungi are typically resilient and transmissible human pathogens and thus potentiate the problem of AMR.^{10,21,47} AFR mainly occurs via efflux pump activation, drug target overexpression and amino acid substitution,^{8,39,48,49} with a number of studies now reporting AFR against commonly used antifungals.^{8,50–57} This situation is likely to worsen unless proactively addressed.⁹ This is a concern because AFR limits the number of effective antifungal therapies and causes treatment to be expensive, especially in low- and middle-income countries (LMICs).^{11,13,23,58,59}

The ever-growing problem of AFR requires development and successful implementation of multiple strategies within countries, especially among LMICs.^{5,60,61} The first step in this process is to assess current awareness, knowledge and attitudes towards antifungals and AFR among key stakeholder groups in order to develop pertinent interventions to reduce identified problems. Secondly, to develop and implement pertinent strategies, which could include educational strategies as well as targeted antimicrobial stewardship programmes (ASPs).^{60,62,63} This is essential with sustainable antifungal stewardship programmes (AFSPs) needing to be developed and promoted globally to reduce AFR.^{17,23,64–69}

As mentioned, the majority of studies assessing antimicrobial utilization and AMR in Zambia among patients, as well as ASPs, have typically focused on antibiotics, antivirals and anti-TB drugs, not antifungals.^{24,70–76} This needs to be urgently addressed given that Zambia has a significant population grappling with immune system-compromising diseases including HIV/AIDS, which presents a high risk of opportunistic diseases including fungal infections.^{76–78} Consequently, we sought to address this evidence gap by initially assessing the knowledge, attitudes and practices (KAP) of student pharmacists at the University of Zambia regarding AFR and AFS. This builds on similar studies regarding antibiotics and AMR among healthcare students in Zambia, as well as healthcare professionals (HCPs).^{79–81} The findings can subsequently be used to refine educational programmes in universities to help improve antifungal utilization in the future.

We started with student pharmacists as they are the future community pharmacists, with pharmacists globally increasingly dealing with infectious diseases and their treatment following COVID-19.^{82–84} In view of this, it is important that community pharmacists are fully conversant with key aspects of antifungals and AFR. We are aware in Zambia that up to 100% of pharmacies dispense antibiotics without a prescription.⁸⁵ However, we are also aware that in Kenya and Namibia well-trained pharmacists give advice on the appropriate management of self-limiting infectious diseases without resorting to antimicrobials.^{84,86–88} In view of this, we believe the future pharmacists in Zambia should be able to provide appropriate advice to patients without unnecessarily exposing them to antifungals and AFR, especially those patients without medical prescriptions.

Materials and methods

Study design, population and site

A cross-sectional study was conducted among undergraduate pharmacy students at the University of Zambia between June 2023 and July 2023, according to the STROBE guidelines. To be eligible, participants had to be enrolled and registered as undergraduate pharmacy students at the University of Zambia, with active participation after obtaining informed and written consent.

The sample size was estimated using Taro Yamane's formula,⁸⁹ by employing a finite population of 601 undergraduate pharmacy students stratified as 196 second-year students, 158 third-year students, 133 fourth-year students and 92 fifth-year students. After adjusting for a 10% non-response, our final minimum required sample size was 265 students. The study population was classified into strata based on the year of study. All participants were identified using class registers and were randomly sampled using computer-generated random numbers.




Figure 1. Knowledge directly (→) affecting outcome or mediated indirectly (→) by attitude.

Data collection

Data were collected using an adapted questionnaire from two recent studies.^{90,91} Public health experts from the University of Zambia and the Copperbelt University subsequently reviewed the data collection tool for face and content validity. Hence, the questionnaire was pre-validated for simplicity, clarity, understandability, relevance and accuracy. The authors chose to adapt the data collection tools on AMR and AMS because there were no KAP studies that were done on AFR and AFS prior to the study. The questionnaire had four sections, namely: **Section A:** Sociodemographic characteristics of participants assessed using five questions; **Section B:** 10 questions on knowledge of AFR and AFS; **Section C:** 10 questions on attitude towards AFR and AFS; and **Section D:** 10 questions on practices regarding AFR and AFS. A pilot study was subsequently undertaken with 20 pharmacy students to improve the robustness of the questionnaire. Students who participated in the pilot study were excluded from the main study. The reliability of the questionnaire was determined using a Cronbach's α value. Hence, with a Cronbach's α value of 0.827 demonstrating an acceptable internal consistency, the final questionnaire was seen as reliable. The participants were recruited and provided with a self-administered questionnaire, which was submitted to the data collectors on completion. Data collection was undertaken by three data collectors (S.M., P.C. and W.M.) and lasted for 20 to 30 min per participant. A total of 420 questionnaires were administered to the identified participants.

Study measures

The main outcomes of this study were knowledge, attitudes and practices towards AFR and AFS (coded as good = 1, poor = 0). The KAP questions had three options (yes, no or neutral). Item scores were summed to obtain a composite score for each of the three options (Table S1, available as [Supplementary data](#) at [JAC-AMR Online](#)). The continuous scores were categorized to obtain binary variables for good knowledge, positive attitude and good practice using a cut-off value of 80%. We hypothesized that students with good knowledge and attitudes would have good practices towards AFR and AFS. In addition, the effect of knowledge on practice towards AFR and AFS will be mediated by students' attitudes (Figure 1).

Statistical analysis

We reported frequencies and percentages for categorical variables. The Pearson chi-squared test was used to compare scores of KAP among the students. KAP scores were calculated by adding correct responses to obtain a composite score. The scores were categorized into a binary variable using a cut-off value of 80% coded as $\geq 80\% = 1$ ('good knowledge, attitude and practice') and $< 80\% = 0$ ('poor knowledge, attitude and practice'). Separate logistic regression models were used to calculate crude and adjusted ORs (AORs) with respective 95% CIs. All three multivariable models used significant variables at 20% from the univariable analysis. An investigator-led stepwise regression technique was used to

drop off variables with high P values sequentially until a parsimonious model was built. Interactions were assessed between the final model's significant variables, and none reached any statistical significance.

We further conducted generalized structural equation modelling to assess the interrelationships between variables and their mechanisms of association. We calculated direct, indirect and total effects to examine how knowledge affected practice towards AFR and AFS, part of which could occur through attitude. The effect of knowledge on practice towards AFR and AFS while controlling for attitude is called the direct effect. On the other hand, the indirect effect occurs because knowledge affects the attitude, which in turn affects the practice towards antifungal resistance. Ultimately, the direct and indirect effects form the total effects on the outcome (practice towards AFR and AFS). All models were independently adjusted for year of study. Bootstraps (50 replications) were used to compute standard errors for effects estimates. All statistical analyses were performed in STATA (version 17; StataCorp LP), and the significance level was set at α less than 5%.

Ethics

This study was approved by the University of Zambia Health Sciences Research Ethics Committee (UNZAHSREC), approval number 2022112301176. Participants provided written informed consent after being informed of the purpose of this study. Participation in this study was voluntary and strictly for those who provided consent.

Results

Characteristics of study participants

Of the 420 questionnaires distributed, 412 were completed and returned, resulting in a response rate of 98%. The majority of the participants were female (55.8%), aged between 18 and 25 years (81.6%), unmarried (91.8%) and resided in urban areas (80.6%) (Table 1).

KAP towards antifungals and AFR

Most students had good knowledge (85.9%), attitudes (86.7%) and practice (65.8%) towards AFR and AFS (Table 2). The highest proportion of participants who had good practice was among the third-year students (71.7%). There was no evidence though of an association between the year of study and scores for knowledge and attitudes.

This study found that 97.3% of the participants knew the definition of AFR, 93.7% could give examples of antifungals, 93.9% knew that misuse of antifungals contributes to AFR, and 89.3% knew that AFR can lead to prolonged illnesses and higher mortality. The lowest score among students concerned over-the-counter antifungal medicines not leading to AFR (Table 3).

Most of the participating pharmacy students (90.1%) knew that AFR is a significant public health concern; however, the majority (51.2%) felt that the current training on antifungals and AFR in the university was not sufficient. Most students (89.8%) were also aware that the misuse and overuse of antifungals contributed to AFR, and 90.5% believed that infection prevention and control measures could help address AFR (Table 3).

This study also found that the prevalence of accessing antifungal medicines without a prescription was 30.2%. Additionally, 73.5% of participants did not recommend antifungals to their families or friends, did not use antifungals for UTIs, did not use antifungals when they had a cold, and did not participate in

any AFSPs. Finally, 81.1% reported that they sought additional education or training on antifungals and AFR (Table 3).

Factors associated with KAP towards AFR and AFS

Table 4 shows the results from the multivariable analysis. Male participants were less likely to report good knowledge of AFR and AFS than female participants (AOR=0.55, 95% CI: 0.31–0.98). Similarly, fourth-year students versus second-year students (AOR=0.44, 95% CI: 0.20–0.98) and students residing in urban areas versus rural/peri-urban (AOR=0.35, 95% CI: 0.13–0.91) were less likely to report a positive attitude.

Furthermore, fourth-year students were less likely to report good practices than second-year students (AOR=0.48, 95% CI: 0.27–0.85). On the other hand, married students were more likely to report good practices than unmarried students (AOR=2.75, 95% CI: 1.13–6.68).

Mediation analysis: effect of knowledge on the practice towards AFR and AFS

Mediation analysis was performed to examine if attitude is a mechanism through which knowledge could affect the practice towards AFR and AFS (Table 5). Good knowledge was significantly

associated with good practice, both directly and indirectly, through attitude. The total effect of good knowledge and attitude on good practices was 1.47-fold.

Discussion

To the best of our knowledge, this is the first study to assess the KAP of undergraduate pharmacy students regarding AFR and AFS in Zambia. Approximately 86% of participating students reported good knowledge and attitude towards AFR and AFS, with approximately 66% reporting good practice. Male students were less likely to report good knowledge of AFR and AFS than female students. Similarly, fourth-year students versus second years, and students residing in urban areas, were less likely to report positive attitudes. Furthermore, fourth-year students compared with second-year students were less likely to report good practices. In mediation analysis, good knowledge was significantly associated with good practice, both directly and indirectly, through attitude.

Encouragingly, most pharmacy students had a strong understanding of AFR and AFS, similar to previous studies that had assessed students' general knowledge of AMR and AMS across countries.^{80,91–94} However, our findings were better than those seen in other studies involving students.^{95,96} The good knowledge reported in our study may be because pharmacy students in Zambia are exposed to information about antifungals, antibiotics, antivirals and antiprotozoal drugs during training. Reassuringly as well, most pharmacy students knew the term AFR, examples of antifungals, factors that promote AFR, and AFS as a strategy for combating this public health issue. These findings corroborate similar studies where students knew the definition of AMR and predisposing factors as well as AMS/ASPs as ways forward to combat this public health problem.^{97,98} Interestingly, fourth-year students in our study were less likely to report good practices than second-year students, which contrasts with a study in Ghana that found that the level of AMR and AMS knowledge correlated with the year of study.⁹¹ Additionally, female students were more likely to have good knowledge of AFR and AFS than male students. This could be because female individuals tend to seek medical help and visit healthcare facilities where they are likely to receive information about antifungal medicines.

Table 1. Sociodemographic characteristics of participants (N=412)

Variable	Category	n (%)
Age (years)	18–25	336 (81.6)
	26–33	50 (12.1)
	>33	26 (6.3)
Sex	Female	230 (55.8)
	Male	182 (44.2)
Residence	Rural/peri-urban	80 (19.4)
	Urban	332 (80.6)
Marital status	Unmarried	378 (91.8)
	Married	34 (8.3)
Year of study	Second	126 (30.6)
	Third	145 (35.2)
	Fourth	85 (20.6)
	Fifth	56 (13.6)

Table 2. Students' KAP according to the year of study

	Total (N=412)	Year of study				P value
		Second (N=126)	Third (N=145)	Fourth (N=85)	Fifth (N=56)	
Knowledge, n (%)						
Poor	58 (14.1)	19(15.1)	21 (14.5)	11(12.9)	7(12.5)	0.954
Good	354 (85.9)	107(84.9)	124(85.5)	74(87.1)	49 (87.5)	
Attitude, n (%)						
Poor	55(13.4)	14(11.1)	17(11.7)	16(18.8)	8(14.3)	0.373
Good	357(86.7)	112(88.9)	128(88.3)	69(81.2)	48(85.7)	
Practice, n (%)						
Poor	141(34.2)	40(31.8)	41(28.3)	39(45.9)	21(37.5)	0.046
Good	271(65.8)	86(68.3)	104(71.7)	46(54.1)	35(62.5)	

Table 3. Students' responses to the KAP statements

Domain	Yes, n (%)	No, n (%)	Don't know/neutral, n (%)
Knowledge statements			
Antifungal resistance is a phenomenon where fungi become less responsive to antifungal medications.	401 (97.3)	4 (1.0)	7 (1.7)
Fluconazole, amphotericin B, and itraconazole are examples of common antifungal medications.	386 (93.7)	7 (1.7)	19 (4.6)
Misuse or overuse of antifungal medications contributes to the development of antifungal resistance.	387 (93.9)	9 (2.2)	16 (3.9)
Antifungal resistance could lead to prolonged illnesses and higher mortality rates.	368 (89.3)	18 (4.4)	26 (6.3)
Only bacterial infections can develop resistance; fungal infections cannot.	9 (2.2)	381 (92.5)	22 (5.3)
It's important to complete the full course of prescribed antifungal treatment, even if symptoms improve earlier.	403 (97.8)	4 (1.0)	5 (1.2)
Antifungal stewardship programs aim to improve the use of these drugs.	388 (94.2)	8 (1.9)	16 (3.9)
Over-the-counter antifungal medications cannot lead to antifungal resistance.	49 (11.9)	321 (77.9)	42 (10.2)
Patient adherence to the prescribed antifungal regimen is crucial for effective treatment.	375 (91.0)	12 (2.9)	25 (6.07)
Regular diagnostics are not necessary when prescribing antifungal treatment.	339 (82.3)	37 (9.0)	36 (8.7)
Attitude statements			
Antifungal resistance is a significant public health concern.	371 (90.1)	12 (2.9)	29 (7.0)
The current training and education about the proper use of antifungals and antimicrobial resistance are sufficient.	132 (32.0)	211 (51.2)	69 (16.8)
It is okay to prescribe antifungal medication even without a confirmed fungal infection.	15 (3.6)	387 (93.9)	10 (2.4)
All healthcare students should participate in antifungal stewardship programs.	379 (92.0)	1 (0.2)	32 (7.8)
Patient non-compliance to antifungal medicines contributes to the occurrence of antifungal resistance.	367 (89.1)	22 (5.3)	23 (5.6)
Overuse or misuse of antifungal medications in healthcare practices is a public health concern.	370 (89.8)	17 (4.1)	25 (6.1)
The proper use of antifungal medicines is a critical part of effective patient care.	396 (96.1)	5 (1.2)	11 (2.7)
It's necessary to discuss antifungal resistance and its implications with patients.	405 (98.3)	2 (0.5)	5 (1.2)
I believe that more research is needed in the field of antifungal resistance.	399 (96.8)	4 (1.0)	9 (2.2)
Preventive measures, such as infection control and prophylaxis are important in managing antifungal resistance.	373 (90.5)	6 (1.5)	33 (8.0)
Practice statements			
I bought antifungal medicines without a prescription.	124 (30.2)	256 (62.1)	32 (7.8)
When my family/friend is sick, I recommend buying antifungals.	62 (15.1)	303 (73.5)	47 (11.4)
I use antifungals because of advice from friends and family.	56 (13.6)	323 (78.4)	33 (8.0)
I use antifungals when I have a urinary tract infection.	95 (23.1)	277 (67.2)	40 (9.7)
I use antifungal medicines when I have a cold.	12 (2.9)	384 (93.2)	16 (3.9)
I seek additional education or training on antifungal medications and resistance.	334 (81.1)	39 (9.5)	39 (9.5)
Prescribing physicians and students are the only professionals who need to understand antifungal stewardship.	29 (7.0)	358 (86.9)	25 (6.1)
I participate in antifungal stewardship and awareness programs.	151 (36.7)	198 (48.1)	63 (15.3)
I keep myself updated about the latest research and guidelines regarding antifungal medications and antimicrobial resistance.	177 (43.0)	146 (35.4)	89 (21.6)
Formal teaching on the proper usage of antifungals among healthcare students is an intervention that may minimize the phenomena of antifungal resistance.	391 (94.9)	13 (3.2)	8 (1.9)

The present study found that most students had positive attitudes towards AFR and AFS, similar to previous studies on AMR in Zambia.^{79,80} However, our study found positive attitudes compared with the negative attitudes towards AMR and ABR among students in China.³² Despite most students having positive attitudes towards AFR and AFS in our study, 51.2% felt that the training they received on antifungals, AFR and AFS was insufficient. However, this is similar to a study in Colombia where most students felt the information they received on AMR and AMS during

training was insufficient.⁹⁹ Consequently, this calls for improved AMR and AMS information in undergraduate curricula in Zambia and beyond as well as integrating AFR into the curricula. We will continue to monitor this in the future.

The present study found slightly lower scores in practices of students regarding AFR and AFS compared with the scores in knowledge and attitudes, which also needs addressing when updating the curricula. Intriguingly, we found that 30.2% of the students had purchased antifungals without a prescription. This is

Table 4. Predictors of good KAP among Bachelor of Pharmacy students

Variable	Knowledge		Attitude		Practice	
	AOR (95% CI)	P value	AOR (95% CI)	P value	AOR (95% CI)	P value
Year of study						
Second	Ref		Ref		Ref	0.646
Third	1.07 (0.54–2.10)	0.844	0.88 (0.41–1.88)	0.749	1.13 (0.67–1.91)	0.013
Fourth	1.09 (0.48–2.44)	0.841	0.44 (0.20–0.98)	0.043	0.48 (0.27–0.85)	0.22
Fifth	1.17 (0.46–2.99)	0.74	0.60 (0.23–1.56)	0.295	0.66 (0.33–1.29)	
Sex						
Female	Ref					
Male	0.55 (0.31–0.98)	0.042				
Marital status						
Unmarried			Ref		Ref	
Married			3.33 (0.75–14.74)	0.113	2.75 (1.13–6.68)	0.026
Residence						
Rural/peri-urban			Ref			
Urban			0.35 (0.13–0.91)	0.032		

AOR, adjusted odds ratio; 95%CI, 95% confidence intervals. Boldface indicates statistical significance at 5%. Good knowledge, attitude and practice were scores of 80% or above.

Table 5. Mediation analysis of the influence of knowledge on the practice towards AFR and AFS

Effects	Mediator (attitude)	
	OR (95% CI)	P value
Total	1.47 (0.82–2.12)	<0.001
Indirect	0.18 (0.01–0.36)	0.042
Direct	1.27 (0.57–1.97)	<0.001

The model was adjusted for year of study.

only important if antifungals were inappropriate for the infection, with countries typically making antifungals available over the counter. We are aware of the appreciable misuse and overuse of antifungals, which needs to be avoided to reduce AFR. Our findings also revealed that very few students participated in AFS and awareness programmes. Additionally, very few students updated themselves about the latest research and guidelines regarding antifungal medications and AMS. These behaviours contributed to the low scores in practice recorded among the study participants. Community pharmacists and their assistants can play a key role here. Consequently, it is important that student pharmacists participate in AFS and awareness programmes during their training, which was not the case in our study. In addition, students pharmacists must take part in AFSPs to improve the future use of antifungals to reduce AFR. Alongside this, the students must update themselves on the latest research and guidelines to improve the care of patients, which is not happening currently. One surprising finding of our study was that fourth-year students reported lower rates of good practices compared with their second-year counterparts. This is because fourth-year students, having had more exposure to clinical settings, may feel overconfident and more inclined to self-medicate, leading to poor

practices for themselves and patients post-qualification. Studies from Ethiopia and other countries also found that students in higher years of study tend to self-medicate because they learn more practical-oriented courses that increase their understanding of diseases and use of medicines.^{100–103} The observed variations suggest that educational strategies, and their impact on students' practices, can differ by region and institution; consequently, any updated educational input needs to be targeted to the specific student body in question. Future research should explore the underlying reasons for this discrepancy to inform the development of more effective educational programmes.

Additionally, organizations such as the Pharmaceutical Society of Zambia (PSZ) should introduce short courses and continuing professional development (CPD) programmes that focus on AFS and the role of AFS. The Ministry of Health and the Zambia National Public Health Institute (ZNPHI) should also champion the promotion of research and awareness campaigns on AFR and support AFSPs.²²

We are aware that there are limitations in our study. Firstly, the study was only conducted at a single university in Zambia. This implies that the findings of our study may not be generalized to all the universities in Zambia. Secondly, we employed a quantitative, cross-sectional design, which may constrain the depth of information gathered. The approach we used in our study may affect the depth of findings as participants are not allowed to give their detailed opinion on a subject matter. Despite these limitations, since our study is the first to highlight students' KAP concerning AFR and AFSPs in Zambia, we believe the findings can serve as an impetus for researchers, health authorities and policymakers to integrate AFR into programmes to address AFR in Zambia and beyond. Further, we recommend multicentre studies on AFR and AFS among students in all universities in Zambia. Further, future studies should be conducted to explore the KAP of healthcare professionals on AFR and AFS.

Conclusions

Overall, most students possessed good knowledge and attitudes towards AFR and AFS, which is encouraging since AFR and AFSs are a poorly researched and under-researched field across Africa including Zambia. This underscores the need for targeted educational interventions in areas where students scored poorly such as insufficient training on AFR, not participating in AFS, not being up to date with information on AFR and AFS, and addressing access to antifungals without prescriptions.

Acknowledgements

We acknowledge the pharmacy students from the University of Zambia for participating in this study. Additionally, we acknowledge the University of Zambia management for allowing us to conduct data collection from the institution and for providing us with access to most of the articles cited in this paper through the e-library services.

Funding

This research was internally funded as part of routine studies into AMR and AMS.

Transparency declarations

All author declare no conflicts of interest. All the authors do not have any financial interests or connections that may directly or indirectly raise concerns of bias in the work reported or the conclusions, implications or opinions made in this publication.

Supplementary data

Table S1 is available as [Supplementary data](#) at JAC-AMR Online.

References

- 1 Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health* 2015; **109**: 309–18. <https://doi.org/10.1179/2047773215Y.0000000030>
- 2 Huemer M, Mairpady Shambat S, Brugger SD *et al.* Antibiotic resistance and persistence—implications for human health and treatment perspectives. *EMBO Rep* 2020; **21**: e51034. <https://doi.org/10.15252/embr.202051034>
- 3 Gautam A. Antimicrobial resistance: the next probable pandemic. *JJ Nepal Med Assoc* 2022; **60**: 225–8. <https://doi.org/10.31729/jnma.7174>
- 4 de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? *PLoS Med* 2016; **13**: e1002184. <https://doi.org/10.1371/journal.pmed.1002184>
- 5 Aslam B, Khurshid M, Arshad MI *et al.* Antibiotic resistance: One Health One World outlook. *Front Cell Infect Microbiol* 2021; **11**: 771510. <https://doi.org/10.3389/fcimb.2021.771510>
- 6 Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. *Open Forum Infect Dis* 2022; **9**: ofab593. <https://doi.org/10.1093/ofid/ofab593>
- 7 Hofer U. The cost of antimicrobial resistance. *Nat Rev Microbiol* 2019; **17**: 3. <https://doi.org/10.1038/s41579-018-0125-x>
- 8 Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and

management. *Lancet Infect Dis* 2017; **17**: e383–e92. [https://doi.org/10.1016/S1473-3099\(17\)30316-X](https://doi.org/10.1016/S1473-3099(17)30316-X)

9 Fisher MC, Alastruey-Izquierdo A, Berman J *et al.* Tackling the emerging threat of antifungal resistance to human health. *Nat Rev Microbiol* 2022; **20**: 557–71. <https://doi.org/10.1038/s41579-022-00720-1>

10 Banerjee S, Denning DW, Chakrabarti A. One health aspects & priority roadmap for fungal diseases: a mini-review. *Indian J Med Res* 2021; **153**: 311–9. https://doi.org/10.4103/ijmr.IJMR_768_21

11 de Oliveira HC, Bezerra BT, Rodrigues ML. Antifungal development and the urgency of minimizing the impact of fungal diseases on public health. *ACS Bio Med Chem Au* 2023; **3**: 137–46. <https://doi.org/10.1021/acsbiochemchem.2c00055>

12 Hendrickson JA, Hu C, Aitken SL *et al.* Antifungal resistance: a concerning trend for the present and future. *Curr Infect Dis Rep* 2019; **21**: 47. <https://doi.org/10.1007/s11908-019-0702-9>

13 Almeida F, Rodrigues ML, Coelho C. The still underestimated problem of fungal diseases worldwide. *Front Microbiol* 2019; **10**: 214. <https://doi.org/10.3389/fmicb.2019.00214>

14 Firacative C. Invasive fungal disease in humans: are we aware of the real impact? *Mem Inst Oswaldo Cruz* 2020; **115**: e200430. <https://doi.org/10.1590/0074-02760200430>

15 Slavin M, van Hal S, Sorrell TC *et al.* Invasive infections due to filamentous fungi other than *Aspergillus*: epidemiology and determinants of mortality. *Clin Microbiol Infect* 2015; **21**: 490.e1–10. <https://doi.org/10.1016/j.cmi.2014.12.021>

16 Gold JAW, Ahmad FB, Cisewski JA *et al.* Increased deaths from fungal infections during the coronavirus disease 2019 pandemic—national vital statistics system, United States, January 2020–December 2021. *Clin Infect Dis* 2023; **76**: e255–e62. <https://doi.org/10.1093/cid/ciac489>

17 Rabaan AA, Sulaiman T, Al-Ahmed SH *et al.* Potential strategies to control the risk of antifungal resistance in humans: a comprehensive review. *Antibiotics* 2023; **12**: 608. <https://doi.org/10.3390/antibiotics12030608>

18 Bongomin F, Gago S, Oladele RO *et al.* Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi* 2017; **3**: 57. <https://doi.org/10.3390/jof3040057>

19 Kainz K, Bauer MA, Madeo F *et al.* Fungal infections in humans: the silent crisis. *Microb Cell* 2020; **7**: 143–5. <https://doi.org/10.15698/mic2020.06.718>

20 Benedict K, Jackson BR, Chiller T *et al.* Estimation of direct healthcare costs of fungal diseases in the United States. *Clin Infect Dis* 2019; **68**: 1791–7. <https://doi.org/10.1093/cid/ciy776>

21 Vitiello A, Ferrara F, Boccellino M *et al.* Antifungal drug resistance: an emergent health threat. *Biomedicines* 2023; **11**: 1063. <https://doi.org/10.3390/biomedicines11041063>

22 Mudenda S, Chabalenge B, Kasanga M *et al.* Antifungal resistance and stewardship: a call to action in Zambia. *Pan Afr Med J* 2023; **45**: 152. <https://doi.org/10.11604/pamj.2023.45.152.41232>

23 Johnson MD, Lewis RE, Dodds Ashley ES *et al.* Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. *J Infect Dis* 2020; **222** Suppl 3: S175–S98. <https://doi.org/10.1093/infdis/jiaa394>

24 Nowbuth A, Asombang A, Tazikeng N *et al.* Antimicrobial resistance in Zambia: a systematic review. *Int J Infect Dis* 2022; **116**: S17–S8. <https://doi.org/10.1016/j.ijid.2021.12.042>

25 Iskandar K, Molinier L, Hallit S *et al.* Drivers of antibiotic resistance transmission in low- and middle-income countries from a “one health” perspective—a review. *Antibiotics* 2020; **9**: 372. <https://doi.org/10.3390/antibiotics9070372>

26 Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf* 2014; **5**: 229–41. <https://doi.org/10.1177/2042098614554919>

- 27 Torres NF, Chibi B, Kuupiel D et al. The use of non-prescribed antibiotics; prevalence estimates in low-and-middle-income countries. A systematic review and meta-analysis. *Arch Public Health* 2021; **79**: 2. <https://doi.org/10.1186/s13690-020-00517-9>
- 28 Belachew SA, Hall L, Selvey LA. Non-prescription dispensing of antibiotic agents among community drug retail outlets in sub-Saharan African countries: a systematic review and meta-analysis. *Antimicrob Resist Infect Control* 2021; **10**: 13. <https://doi.org/10.1186/s13756-020-00880-w>
- 29 Sono TM, Yeika E, Cook A et al. Current rates of purchasing of antibiotics without a prescription across sub-Saharan Africa; rationale and potential programmes to reduce inappropriate dispensing and resistance. *Expert Rev Anti Infect Ther* 2023; **21**: 1025–55. <https://doi.org/10.1080/14787210.2023.2259106>
- 30 Tangcharoensathien V, Chanvatik S, Kosiyaporn H et al. Population knowledge and awareness of antibiotic use and antimicrobial resistance: results from national household survey 2019 and changes from 2017. *BMC Public Health* 2021; **21**: 2188. <https://doi.org/10.1186/s12889-021-12237-y>
- 31 Simegn W, Moges G. Awareness and knowledge of antimicrobial resistance and factors associated with knowledge among adults in Dessie city, northeast Ethiopia: community-based cross-sectional study. *PLoS One* 2022; **17**: e0279342. <https://doi.org/10.1371/journal.pone.0279342>
- 32 Wang Y, Guo F, Wei J et al. Knowledge, attitudes and practices in relation to antimicrobial resistance amongst Chinese public health undergraduates. *J Glob Antimicrob Resist* 2020; **23**: 9–15. <https://doi.org/10.1016/j.jgar.2020.07.023>
- 33 Nicola AM, Albuquerque P, Paes HC et al. Antifungal drugs: new insights in research & development. *Pharmacol Ther* 2019; **195**: 21–38. <https://doi.org/10.1016/j.pharmthera.2018.10.008>
- 34 Gnat S, Łagowski D, Nowakiewicz A et al. A global view on fungal infections in humans and animals: opportunistic infections and microsporidiosis. *J Appl Microbiol* 2021; **131**: 2095–113. <https://doi.org/10.1111/jam.15032>
- 35 Bajpai VK, Khan I, Shukla S et al. Invasive fungal infections and their epidemiology: measures in the clinical scenario. *Biotechnol Bioprocess Eng* 2019; **24**: 436–44. <https://doi.org/10.1007/s12257-018-0477-0>
- 36 Jabeen K, Farooqi J, Mirza S et al. Serious fungal infections in Pakistan. *Eur J Clin Microbiol Infect Dis* 2017; **36**: 949–56. <https://doi.org/10.1007/s10096-017-2919-6>
- 37 Shu Kurizky P, Dos Santos Neto LL, Barbosa Aires R et al. Opportunistic tropical infections in immunosuppressed patients. *Best Pract Res Clin Rheumatol* 2020; **34**: 101509. <https://doi.org/10.1016/j.berh.2020.101509>
- 38 Valladales-Restrepo LF, Ospina-Cano JA, Aristizábal-Carmona BS et al. Study of prescription-indication of outpatient systemic anti-fungals in a Colombian population. A cross-sectional study. *Antibiotics* 2022; **11**: 1805. <https://doi.org/10.3390/antibiotics11121805>
- 39 Houšť J, Spižek J, Havlíček V. Antifungal drugs. *Metabolites* 2020; **10**: 106. <https://doi.org/10.3390/metabo10030106>
- 40 Dismukes WE. Introduction to antifungal drugs. *Clin Infect Dis* 2000; **30**: 653–7. <https://doi.org/10.1086/313748>
- 41 Nami S, Aghebati-Maleki A, Morovati H et al. Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases. *Biomed Pharmacother* 2019; **110**: 857–68. <https://doi.org/10.1016/j.biopha.2018.12.009>
- 42 Khairy WA, Nasser HA, Sarhan MD et al. Prevalence and predictors of self-medication with antifungal drugs and herbal products among university students: a cross-sectional study from Egypt. *Risk Manag Healthc Policy* 2021; **14**: 2191–200. <https://doi.org/10.2147/RMHP.S308400>
- 43 Mushi M, Masewa B, Jande M et al. Prevalence and factor associated with over-the-counter use of antifungal agents', in Mwanza City, Tanzania. *Tanzania J Health Res* 2017; **19**. <https://doi.org/10.4314/thrb.v19i1.8>
- 44 Robertson E, Abera C, Wood K et al. Striving towards access to essential medicines for human and animal health; a situational analysis of access to and use of antifungal medications for histoplasmosis in Ethiopia. *PLoS One* 2023; **18**: e0278964. <https://doi.org/10.1371/journal.pone.0278964>
- 45 Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. *Drug Discov Today Technol* 2014; **11**: 65–71. <https://doi.org/10.1016/j.ddtec.2014.02.005>
- 46 Hossain CM, Ryan LK, Gera M et al. Antifungals and drug resistance. *Encyclopedia* 2022; **2**: 1722–37. <https://doi.org/10.3390/encyclopedia2040118>
- 47 Chowdhary A, Sharma C, Meis JF. *Candida auris*: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. *PLoS Pathog* 2017; **13**: e1006290. <https://doi.org/10.1371/journal.ppat.1006290>
- 48 Cowen LE, Sanglard D, Howard SJ et al. Mechanisms of antifungal drug resistance. *Cold Spring Harb Perspect Med* 2014; **5**: a019752. <https://doi.org/10.1101/cshperspect.a019752>
- 49 Revie NM, Iyer KR, Robbins N et al. Antifungal drug resistance: evolution, mechanisms and impact. *Curr Opin Microbiol* 2018; **45**: 70–6. <https://doi.org/10.1016/j.mib.2018.02.005>
- 50 Alcoceba E, Gómez A, Lara-Esbri P et al. Fluconazole-resistant *Candida parapsilosis* clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. *Clin Microbiol Infect* 2022; **28**: 1113–9. <https://doi.org/10.1016/j.cmi.2022.02.025>
- 51 Kessler SQS, Lang PM, Dal-Pizzol TS et al. Resistance profiles to antifungal agents in *Candida albicans* isolated from human oral cavities: systematic review and meta-analysis. *Clin Oral Investig* 2022; **26**: 6479–89. <https://doi.org/10.1007/s00784-022-04716-2>
- 52 Berkow EL, Lockhart SR. Fluconazole resistance in *Candida* species: a current perspective. *Infect Drug Resist* 2017; **10**: 237–45. <https://doi.org/10.2147/IDR.S118892>
- 53 Arendrup MC, Patterson TF. Multidrug-resistant *Candida*: epidemiology, molecular mechanisms, and treatment. *J Infect Dis* 2017; **216** Suppl 3: S445–S51. <https://doi.org/10.1093/infdis/jix131>
- 54 Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. *Antibiotics (Basel)* 2020; **9**: 312. <https://doi.org/10.3390/antibiotics9060312>
- 55 Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. *Infect Drug Resist* 2017; **10**: 249–59. <https://doi.org/10.2147/IDR.S124918>
- 56 Whaley SG, Berkow EL, Rybak JM et al. Azole antifungal resistance in *Candida albicans* and emerging non-*albicans* *Candida* species. *Front Microbiol* 2016; **7**: 2173. <https://doi.org/10.3389/fmicb.2016.02173>
- 57 Denning DW. Antifungal drug resistance: an update. *Eur J Hosp Pharm* 2022; **29**: 109–12. <https://doi.org/10.1136/ejhpharm-2020-002604>
- 58 Borba HHL, Steimbach LM, Riveros BS et al. Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. *Mycoses* 2018; **61**: 754–63. <https://doi.org/10.1111/myc.12801>
- 59 Ibe C, Otu AA. Recent advances and challenges in the early diagnosis and management of invasive fungal infections in Africa. *FEMS Yeast Res* 2022; **22**: foac048. <https://doi.org/10.1093/femsyr/foac048>
- 60 Godman B, Ekwuenu A, Haque M et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. *Life* 2021; **11**: 528. <https://doi.org/10.3390/life11060528>
- 61 Mudenda S, Chabalenge B, Daka V et al. Global strategies to combat antimicrobial resistance: a one health perspective. *Pharmacol Pharm* 2023; **14**: 271–328. <https://doi.org/10.4236/pp.2023.148020>

- 62** Pierce J, Apisarntharak A, Schellack N *et al.* Global antimicrobial stewardship with a focus on low- and middle-income countries. *Int J Infect Dis* 2020; **96**: 621–9. <https://doi.org/10.1016/j.ijid.2020.05.126>
- 63** Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. *JAC Antimicrob Resist.* 2019; **1**: dlz072. <https://doi.org/10.1093/jacamr/dlz072>
- 64** Ray A, Das A, Panda S. Antifungal stewardship: what we need to know. *Indian J Dermatol Venereol Leprol* 2023; **89**: 5–11. https://doi.org/10.25259/IJDVL_91_2022
- 65** Kara E, Metan G, Bayraktar-Ekincioglu A *et al.* Implementation of pharmacist-driven antifungal stewardship program in a tertiary care hospital. *Antimicrob Agents Chemother* 2021; **65**: e0062921. <https://doi.org/10.1128/AAC.00629-21>
- 66** Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. *Virulence* 2017; **8**: 658–72. <https://doi.org/10.1080/21505594.2016.1226721>
- 67** Apisarntharak A, Yatraser A, Mundy LM. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. *Infect Control Hosp Epidemiol* 2010; **31**: 722–7. <https://doi.org/10.1086/653616>
- 68** Micallef C, Aliyu SH, Santos R *et al.* Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. *J Antimicrob Chemother* 2015; **70**: 1908–11. <https://doi.org/10.1093/jac/dkv040>
- 69** Aldossary S, Shah A. Healthcare utilization and impact of antifungal stewardships within respiratory care settings: a systematic literature review. *Mycopathologia* 2021; **186**: 673–84. <https://doi.org/10.1007/s11046-021-00547-z>
- 70** Chiyangi H, Muma JB, Malama S *et al.* Identification and antimicrobial resistance patterns of bacterial enteropathogens from children aged 0–59 months at the university teaching hospital, Lusaka, Zambia: a prospective cross sectional study. *BMC Infect Dis* 2017; **17**: 117. <https://doi.org/10.1186/s12879-017-2232-0>
- 71** Mudenda S, Nsofu E, Chisha P *et al.* Prescribing patterns of antibiotics according to the WHO AWaRe classification during the COVID-19 pandemic at a teaching hospital in Lusaka, Zambia: implications for strengthening of antimicrobial stewardship programmes. *Pharmacoepidemiology* 2023; **2**: 42–53. <https://doi.org/10.3390/pharma2010005>
- 72** Mudenda S, Chomba M, Chabalenge B *et al.* Antibiotic prescribing patterns in adult patients according to the WHO AWaRe classification: a multi-facility cross-sectional study in primary healthcare hospitals in Lusaka, Zambia. *Pharmacol Pharm* 2022; **13**: 379–92. <https://doi.org/10.4236/pp.2022.1310029>
- 73** Samutela MT, Kalonda A, Mwansa J *et al.* Molecular characterisation of methicillin-resistant *Staphylococcus aureus* (MRSA) isolated at a large referral hospital in Zambia. *Pan Afr Med J* 2017; **26**: 108. <https://doi.org/10.11604/pamj.2017.26.108.10982>
- 74** Yamba K, Lukwesa-Musyanyi C, Samutela MT *et al.* Phenotypic and genotypic antibiotic susceptibility profiles of Gram-negative bacteria isolated from bloodstream infections at a referral hospital, Lusaka, Zambia. *PLoS Glob Public Health* 2023; **3**: e0001414. <https://doi.org/10.1371/journal.pgph.0001414>
- 75** Chizimu JY, Solo ES, Bwalya P *et al.* Genomic analysis of *Mycobacterium tuberculosis* strains resistant to second-line anti-tuberculosis drugs in Lusaka, Zambia. *Antibiotics* 2023; **12**: 1126. <https://doi.org/10.3390/antibiotics12071126>
- 76** Mbewe N, Vinikoor MJ, Fwoloshi S *et al.* Advanced HIV disease management practices within inpatient medicine units at a referral hospital in Zambia: a retrospective chart review. *AIDS Res Ther* 2022; **19**: 10. <https://doi.org/10.1186/s12981-022-00433-8>
- 77** Munthali T, Michelo C, Mee P *et al.* Impact of WHO guidelines on trends in HIV testing and ART initiation among children living with HIV in Zambia. *AIDS Res Ther* 2020; **17**: 18. <https://doi.org/10.1186/s12981-020-00277-0>
- 78** Kagujje M, Mubiana ML, Mwamba E *et al.* Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. *BMC Public Health* 2019; **19**: 1329. <https://doi.org/10.1186/s12889-019-7652-x>
- 79** Mudenda S, Mukela M, Matafwali SK *et al.* Knowledge, attitudes, and practices towards antibiotic use and antimicrobial resistance among pharmacy students at the university of Zambia: implications for antimicrobial stewardship programmes. *Sch Acad J Pharm* 2022; **11**: 117–24. <https://doi.org/10.36347/sajp.2022.v11i08.002>
- 80** Zulu AC, Matafwali S, Banda M *et al.* Assessment of knowledge, attitude and practices on antibiotic resistance among undergraduate medical students in the School of Medicine at the University of Zambia. *Int J Basic Clin Pharmacol* 2020; **9**: 263. <https://doi.org/10.18203/2319-2003.ijbcp20200174>
- 81** Mudenda S, Hankombo M, Saleem Z *et al.* Knowledge, attitude, and practices of community pharmacists on antibiotic resistance and antimicrobial stewardship in Lusaka, Zambia. *J Biomed Res Environ Sci* 2021; **2**: 1005–14. <https://doi.org/10.37871/jbres1343>
- 82** Cadogan CA, Hughes CM. On the frontline against COVID-19: community pharmacists' contribution during a public health crisis. *Res Social Adm Pharm* 2021; **17**: 2032–5. <https://doi.org/10.1016/j.sapharm.2020.03.015>
- 83** Hedima EW, Adeyemi MS, Ikunaiye NY. Community pharmacists: on the frontline of health service against COVID-19 in LMICs. *Res Social Adm Pharm* 2021; **17**: 1964–6. <https://doi.org/10.1016/j.sapharm.2020.04.013>
- 84** Kibuule D, Nambahu L, Sefah IA *et al.* Activities in Namibia to limit the prevalence and mortality from COVID-19 including community pharmacy activities and the implications. *Sch Acad J Pharm* 2021; **5**: 82–92. <https://doi.org/10.36347/sajp.2021.v10i05.001>
- 85** Kalungia AC, Burger J, Godman B *et al.* Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. *Expert Rev Anti Infect Ther* 2016; **14**: 1215–23. <https://doi.org/10.1080/14787210.2016.1227702>
- 86** Mukokinya MMA, Opanga S, Oluka M *et al.* Dispensing of antimicrobials in Kenya: a cross-sectional pilot study and its implications. *J Res Pharm Pract* 2018; **7**: 77–82. https://doi.org/10.4103/jrpp.JRPP_17_88
- 87** Opanga S, Rizvi N, Wamaitha A *et al.* Availability of medicines in community pharmacy to manage patients with COVID-19 in Kenya; pilot study and implications. *Sch Acad J Pharm* 2021; **3**: 36–42. <https://doi.org/10.36347/sajp.2021.v10i03.001>
- 88** Muloi D, Fèvre EM, Bettridge J *et al.* A cross-sectional survey of practices and knowledge among antibiotic retailers in Nairobi, Kenya. *J Glob Health* 2019; **9**: 010412. <https://doi.org/10.7189/jogh.09.020412>
- 89** Charan J, Biswas T. How to calculate sample size for different study designs in medical research? *Indian J Psychol Med* 2013; **35**: 121–6. <https://doi.org/10.4103/0253-7176.116232>
- 90** Karuniawati H, Hassali MAA, Suryawati S *et al.* Assessment of knowledge, attitude, and practice of antibiotic use among the population of Boyolali, Indonesia: a cross-sectional study. *Int J Environ Res Public Health* 2021; **18**: 8258. <https://doi.org/10.3390/ijerph18168258>
- 91** Sefah IA, Akwaboah E, Sarkodie E *et al.* Evaluation of healthcare students' knowledge on antibiotic use, antimicrobial resistance and antimicrobial stewardship programs and associated factors in a tertiary university in Ghana: findings and implications. *Antibiotics* 2022; **11**: 1679. <https://doi.org/10.3390/antibiotics11121679>
- 92** Haque M, Ara T, Haq MA *et al.* Antimicrobial prescribing confidence and knowledge regarding drug resistance: perception of medical students

in Malaysia and the implications. *Antibiotics* 2022; **11**: 540. <https://doi.org/10.3390/antibiotics11050540>

93 Hayat K, Jamshed S, Rosenthal M et al. Understanding of pharmacy students towards antibiotic use, antibiotic resistance and antibiotic stewardship programs: a cross-sectional study from Punjab, Pakistan. *Antibiotics* 2021; **10**: 66. <https://doi.org/10.3390/antibiotics10010066>

94 Lubwama M, Onyuka J, Ayazika KT et al. Knowledge, attitudes, and perceptions about antibiotic use and antimicrobial resistance among final year undergraduate medical and pharmacy students at three universities in east Africa. *PLoS One* 2021; **16**: e0251301. <https://doi.org/10.1371/journal.pone.0251301>

95 Nisabwe L, Brice H, Umuhire MC et al. Knowledge and attitudes towards antibiotic use and resistance among undergraduate healthcare students at university of Rwanda. *J Pharm Policy Pract* 2020; **13**: 7. <https://doi.org/10.1186/s40545-020-00207-5>

96 Shah P, Shrestha R, Mao Z et al. Knowledge, attitude, and practice associated with antibiotic use among university students: a survey in Nepal. *Int J Environ Res Public Health* 2019; **16**: 3996. <https://doi.org/10.3390/ijerph16203996>

97 Khan FU, Khan A, Shah S et al. Exploring undergraduate pharmacy students perspectives towards antibiotics use, antibiotic resistance, and antibiotic stewardship programs along with the pharmacy teachers' perspectives: a mixed-methods study from Pakistan. *Front Pharmacol* 2021; **12**: 754000. <https://doi.org/10.3389/fphar.2021.754000>

98 Al-Taani GM, Karasneh RA, Al-Azzam S et al. Knowledge, attitude, and behavior about antimicrobial use and resistance among medical, nursing and pharmacy students in Jordan: a cross sectional study. *Antibiotics* 2022; **11**: 1559. <https://doi.org/10.3390/antibiotics11111559>

99 Higueta-Gutiérrez LF, Roncancio Villamil GE, Jiménez Quiceno JN. Knowledge, attitude, and practice regarding antibiotic use and resistance among medical students in Colombia: a cross-sectional descriptive study. *BMC Public Health* 2020; **20**: 1861. <https://doi.org/10.1186/s12889-020-09971-0>

100 Zeru N, Fetene D, Geberu DM et al. Self-medication practice and associated factors among university of Gondar College of Medicine and Health Sciences students: a cross-sectional study. *Patient Prefer Adherence* 2020; **14**: 1779–90. <https://doi.org/10.2147/PPA.S274634>

101 Pan H, Cui B, Zhang D et al. Prior knowledge, older age, and higher allowance are risk factors for self-medication with antibiotics among university students in southern China. *PLoS One* 2012; **7**: e41314. <https://doi.org/10.1371/journal.pone.0041314>

102 Fatima S, Syed A, Azhar S et al. Medical students perception and practice of self-medication: vision of future practitioner in Pakistan. *Br J Pharm Res* 2017; **17**: 32524. <https://doi.org/10.9734/BJPR/2017/32524>

103 Kasulkar AA, Gupta M. Self medication practices among medical students of a private institute. *Indian J Pharm Sci* 2015; **77**: 178–82. <https://doi.org/10.4103/0250-474X.156569>